Pacritinib(CAS: 937272-79-2)

Pacritinib is a small molecule tyrosine kinase inhibitor. Its chemical formula is C26H21N5O4. This compound is used primarily for the treatment of myelofibrosis, a disorder that causes the bone marrow to produce excessive fibrous tissue and blood cells. It is also being studied for other hematological malignancies.

Pacritinib is mainly used for the treatment of myelofibrosis, a condition characterized by the build-up of scar tissue in the bone marrow. It is also being investigated for potential use in other hematological malignancies, such as acute myeloid leukemia. Its use can improve symptoms and quality of life in patients with myelofibrosis.

Pacritinib is generally safe when used under medical supervision. However, it can cause side effects such as nausea, fatigue, and elevated liver enzymes. Patients should be monitored closely by healthcare professionals. Adverse effects can be minimized with proper dosing and patient education on precautionary measures.

Pacritinib should be stored at room temperature, between 15°C to 30°C (59°F to 86°F), away from direct sunlight and moisture. It should be kept in a tightly sealed container to protect it from environmental conditions that could alter its efficacy or stability. Proper storage is crucial for maintaining the drug's quality and safety during use.